TG Therapeutics Rises on Price Target Hike and New Briumvi Clinical Trial

Key Facts

1Bank of America analyst Alec Stranahan raised the price target for TG Therapeutics from $17 to $20.

2The company initiated a mid-stage study for its drug Briumvi in patients with treatment-resistant schizophrenia.

In a move reflecting cautious optimism over the company's therapeutic expansion, TG Therapeutics shares rose following positive analyst revisions. According to reports, Bank of America analyst Alec Stranahan raised the price target for the stock from $17 to $20. Additionally, the company initiated a mid-stage study for its drug Briumvi, which is now being evaluated for patients with treatment-resistant schizophrenia.

This pipeline expansion comes as biotech firms seek to diversify the indications for their approved therapies, with Briumvi competing in the multiple sclerosis market against heavyweights like Roche's Ocrevus. Per market data, TGTX closed at $56.41 on July 15, 2026, highlighting a significant gap between current market pricing and analyst estimates, as Bank of America maintains an 'Underperform' rating despite the target hike.

Traders should watch for support levels near the recent low of $53.35 (close of July 15, 2026). Looking ahead, broader market sentiment in the high-growth healthcare sector may be influenced by the U.S. Federal Reserve's Monetary Policy Report, which was scheduled for release on July 10, 2026.